Filtered By:
Drug: Flonase

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 392 results found since Jan 2013.

IL-17F, rather than IL-17A, underlies airway inflammation in a steroid-insensitive toluene diisocyanate-induced asthma model
Steroid insensitivity constitutes a major problem for asthma management. Toluene diisocyanate (TDI) is one of the leading allergens of asthma that induces both T-helper Th2 and Th17 responses, and is often associated with poor responsiveness to steroid treatment in the clinic. We sought to evaluate the effects of inhaled and systemic steroids on a TDI-induced asthma model and to find how interleukin (IL)-17A and IL-17F function in this model. BALB/c mice were exposed to TDI for generating an asthma model and were treated with inhaled fluticasone propionate, systemic prednisone, anti-IL-17A, anti-IL-17F, recombinant IL-17A ...
Source: European Respiratory Journal - April 3, 2019 Category: Respiratory Medicine Authors: Chen, R., Zhang, Q., Chen, S., Tang, H., Huang, P., Wei, S., Liang, Z., Chen, X., Tao, A., Yao, L. Tags: Lung biology and experimental studies, Asthma and allergy Original Articles: Basic science and asthma Source Type: research

MP ‐AzeFlu provides rapid and effective allergic rhinitis control: results of a non‐interventional study in Denmark
ConclusionMP ‐AzeFlu provided effective, rapid, and sustained symptom control in a real‐life setting among patients from Denmark. These results align with EU and ARIA objectives and support the effectiveness of MP‐AzeFlu for the treatment of AR in real life.
Source: International Forum of Allergy and Rhinology - March 27, 2019 Category: Allergy & Immunology Authors: Peter A. Haahr, Claus Jacobsen, Maria E. Christensen Tags: ORIGINAL ARTICLE Source Type: research

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial
Conclusions: Triamcinolone acetonide proved to be non-inferior to fluticasone propionate in adult patients with PAR; both treatments decreased rTNSS values and showed a good safety profile.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - March 15, 2019 Category: Allergy & Immunology Source Type: research

Nasal Symptoms Reduction and Decreased Neutrophilia in Japanese Cedar Pollinosis With Prophylactic Treatment With a Combination of Montelukast, Fexofenadine, and Fluticasone Nasal Spray.
CONCLUSION: In PreSyP and PreAsP subjects, treatments with Mo-Fex-Flu were more effective than Cet-Flu to reduce nasal symptom scores. These effects were associated with reduction in the number of neutrophils and mast cells in nasal swabs. PMID: 30821167 [PubMed - as supplied by publisher]
Source: American Journal of Rhinology and Allergy - February 28, 2019 Category: ENT & OMF Authors: Otsuka H, Otsuka K, Matsune S, Okubo K Tags: Am J Rhinol Allergy Source Type: research

Eosinophilic esophagitis: Pathophysiology, diagnosis, and management.
Abstract Eosinophilic esophagitis (EoE) is a multifactorial esophageal inflammation, with a genetic predisposition, which combines a deficient esophageal mucosal barrier, an abnormal immune reaction to environmental allergens mediated by Th2 interleukins, immediate esophageal lesions and dysmotility, with secondary remodeling and fibrosis. Symptoms include reflux, abdominal pain, and food impaction, with a variation according to age. Fibroscopy shows major and minor endoscopic and histologic criteria, with a mucosal count≥15 eosinophils/high power field (Eo/hpf). A new entity has been defined, where gastroesopha...
Source: Archives de Pediatrie - February 27, 2019 Category: Pediatrics Authors: Vinit C, Dieme A, Courbage S, Dehaine C, Dufeu CM, Jacquemot S, Lajus M, Montigny L, Payen E, Yang DD, Dupont C Tags: Arch Pediatr Source Type: research

Lifetime Work Productivity Gains Among Patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) Treated with EDS-FLU
Chronic rhinosinusitis with/without nasal polyps (CRSwNP/CRSsNP) is a debilitating inflammatory disorder commonly diagnosed in working age adults, and is characterized by significant morbidity and poor outcomes with standard medical therapy. CRS affects approximately 15% of adults, generating ∼$60B in lost productivity annually. In two randomized controlled trials in CRSwNP (NAVIGATE I/II), treatment with the exhalation delivery system with fluticasone (EDS-FLU; XHANCE®), was associated with a 52.7% improvement in self-reported work productivity.
Source: Journal of Allergy and Clinical Immunology - February 1, 2019 Category: Allergy & Immunology Authors: Fulton F. Velez, Harry J. Sacks, John C. Messina, Victoria Dennison, Nathaniel Smith, Daniel C. Malone, Ramy A. Mahmoud Source Type: research

Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia
Conclusions: MP-AzeFlu was superior to AZE in reducing moderate-to-severe SAR symptoms, providing earlier and more complete symptom relief.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - January 27, 2019 Category: Allergy & Immunology Source Type: research

MP ‐AzeFlu provides rapid and effective allergic rhinitis control: results of a non‐interventional study in Denmark
ConclusionMP ‐AzeFlu provided effective, rapid, and sustained symptom control in a real‐life setting among patients from Denmark. These results align with EU and ARIA objectives and support the effectiveness of MP‐AzeFlu for the treatment of AR in real life.
Source: International Forum of Allergy and Rhinology - January 19, 2019 Category: Allergy & Immunology Authors: Peter A. Haahr, Claus Jacobsen, Maria E. Christensen Tags: ORIGINAL ARTICLE Source Type: research

Assessment of adherence and asthma medication ratio (AMR) for a once-daily and twice-daily inhaled corticosteroid/long acting beta agonist (ICS/LABA) for asthma
ConclusionsAdherence and treatment persistence were low in both cohorts, however, patients initiating once-daily FF/VI were more likely to be adherent, have an AMR ≥0.5, and were less likely to discontinue therapy compared with patients initiating twice-daily BUD/F. (GSK Study HO1617302/206482)
Source: The Journal of Allergy and Clinical Immunology: In Practice - January 11, 2019 Category: Allergy & Immunology Source Type: research

Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers
MP-AzeFlu, intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP), is superior to AZE or FP alone for treatment of allergic rhinitis (AR). However, the precise anti-inflammato...
Source: Allergy, Asthma and Clinical Immunology - December 18, 2018 Category: Allergy & Immunology Authors: Jordi Roca-Ferrer, Laura Pujols, Maria P érez-González, Isam Alobid, Borja Callejas, Sònia Vicens-Artés, Mireya Fuentes, Antonio Valero, César Picado, Dennis Castor, DucTung Nguyen and Joaquim Mullol Tags: Research Source Type: research

Eosinophilic esophagitis: An evidenced-based approach to diagnosis and treatment.
Authors: Pérez-Martínez I, Rodrigo L, Lucendo AJ Abstract Eosinophilic oesophagitis is a unique form of non-IgE-mediated food allergy characterised by oesophageal eosinophilic infiltration. The prevalence of EoE has grown to currently represent the first cause of dysphagia and food impaction in children and young adults. Avoiding food triggers is the only therapy targeting the cause of the disease, but none of the currently available food allergy tests adequately predicts food triggers for EoE. Strategies based on the empirical elimination of food are the most effective and convenient in clinical practice. Proton...
Source: Medicina Clinica - December 15, 2018 Category: General Medicine Tags: Med Clin (Barc) Source Type: research

Residual Fluticasone in the Oral Cavity after Inhalation with Different Tongue Positions
Publication date: Available online 7 December 2018Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Tatsuyoshi Yokoi, Rieko Kondo, Takahiko Horiguchi
Source: The Journal of Allergy and Clinical Immunology: In Practice - December 7, 2018 Category: Allergy & Immunology Source Type: research

NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps.
CONCLUSIONS: In patients with chronic rhinosinusitis with NP (CRSwNP) who were symptomatic despite high rates of prior intranasal steroid use and/or surgery, EDS-FLU produced statistically significant and clinically meaningful improvements compared to EDS-placebo in multiple subjective and objective outcomes (symptoms, SNOT-22, RSDI, SF-36, PGIC, and NP grade), including all 4 cardinal symptoms of CRSwNP. PMID: 30477309 [PubMed - as supplied by publisher]
Source: American Journal of Rhinology and Allergy - November 27, 2018 Category: ENT & OMF Authors: Sindwani R, Han JK, Soteres DF, Messina JC, Carothers JL, Mahmoud RA, Djupesland PG Tags: Am J Rhinol Allergy Source Type: research

Evaluation of the risk of ocular effects associated with eds-flu
Increased intraocular pressure (IOP) and cataracts are known risks of systemic steroid exposure.  EDS-FLU (exhalation delivery system with fluticasone) 372mcg produces higher systemic exposure than fluticasone nasal spray 400mcg, but lower systemic exposure than orally inhaled fluticasone 440mcg.  Ocular effects were extensively studied in EDS-FLU clinical trials.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: D. Skoner, J. Messina, H. Sacks, J. Carothers, R. Mahmoud Tags: P457 Source Type: research

Adherence with once-daily fluticasone furoate/vilanterol compared to twice-daily budesonide/formoterol or fluticasone propionate/salmeterol in asthma
This study compared adherence among asthma patients using FF/VI and B/F or FP/SAL in a large US claims database.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: C. Averell, R. Stanford, F. Laliberte, J. Wu, G. Germain, M. Duh Tags: P204 Source Type: research